spacer
home > epc > autumn 2017 > ethical approaches
PUBLICATIONS
European Pharmaceutical Contractor

Ethical Approaches

Despite the continuous development of new treatments, availability of efficient and safe methods remains a great unmet need. This term, ‘methods’, refers to the vast range of approaches to chemical and biologic medications, cell-based therapies, medical devices, psychotherapy and so on. Testing new procedures against placebo is thought to provide the most reliable data on the value of a new solution.

However, it is not unusual that this comparison is unfeasible for technical or practical reasons or because it is considered unethical. The latter especially affects the development of treatments for severe diseases or for vulnerable populations, where the use of a placebo instead of an active comparator or standard-of-care may be dangerous for the subject. In some cases, the use of placebos can also be linked with a risk to other people, for example, due to an increased possibility of aggressive or asocial behaviours.

These considerations have fuelled many years of debate over the use of placebos in clinical trials. Regulators, opinion leaders, patient advocates and journalists express their opinions on this matter – noticing a disagreement between the stakeholders is easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Piotr Piotrowski is a Medical Director at KCR and holds a PhD in neurology. He is responsible for cross-therapeutic oversight of new and ongoing company projects from a medical perspective. Piotr’s professional experience includes more than 10 years in medical affairs, preclinical research, clinical development and regulatory affairs in the environment of the world’s top pharma industry and academic entities.

Dr Magdalena Czarnecka is a member of the Commercial Project Support Team at KCR, responsible for landscaping and development of clinical documentation. She gathered her professional experience during preclinical research at Georgetown University in Washington DC, US, and her work for a consulting firm focused on medical technology assessment. Magdalena holds a PhD in physiology and biophysics.

Dr Anna Baran
is a Chief Medical Officer at KCR. She leads the organisation’s early stages of study operations and provides cross-functional support to all service areas, ensuring the smooth integration of medical affairs and regulatory and business development efforts. Throughout her career, Anna has worked closely with recognised authorities across Eastern Europe and has been involved in developing national legislation for clinical trials registration.
spacer
Dr Piotr Piotrowsk
spacer
spacer
spacer
Dr Magdalena Czarnecka
spacer
spacer
spacer
Dr Anna Baran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Celebrates 25 Years of Excellence in Quality Control of Biotherapeutics


More info >>

White Papers

Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles

NanoSight

The study of exosomes and other cell-derived microvesicles is an area of rapidly growing importance and the subject of intense interest and research. The previous lack of suitable methods for their detection, analysis, enumeration and phenotyping is proving to be a significant limitation in these studies. This mini-review shows the degree to which the technique of Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >>

 
Industry Events

LogiMed 2017

18-19 October 2017, Hyperion Hotel, Hamburg

Taking place 18-19th October in Hamburg, LogiMed is Europe’s only dedicated medical device supply chain event bringing together over 150 Medical Device Supply Chain Professionals to network with. With a greater focus on customer collaboration and digital transformation this year’s LogiMed delivers real insights on inventory visibility, supply chain planning, global logistics and digitalization.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement